Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AND017 in Anemia with CKD on Dialysis
NCT05265325Phase 2Completed
- Sponsor
- Kind Pharmaceuticals LLC
- Start
- May 2023
- Primary completion
- Feb 2024
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, randomised, open-label trial of AND017 in anemia of chronic kidney disease (3 arms), sponsored by Kind Pharmaceuticals LLC. Primary endpoints: Incidence of adverse events at 20 weeks and Mean change from baseline in Hb at Week 6. Started May 2023; status: completed.
02
Drugs
AND017
03
Conditions
anemia of chronic kidney disease
Beyond the preview
Go deeper on NCT05265325.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05265325.